Semaglutide-eye-catching results

doi:10.4239/wjd.v14.i4.424

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5260)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

283

WORD

HTML

3659

Figures (1-1)

351

Sum=4329

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

153

Download

307

Sum=460

Publishing Process of This Article

Item

Count

Browse

142

Download

329

Sum=471

Apr 15, 2023 (publication date) through Aug 28, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. Apr 15, 2023; 14(4): 424-434
Published online Apr 15, 2023. doi: 10.4239/wjd.v14.i4.424

Open in New Tab Full Size Figure Download Figure

Figure 1 Main mechanisms involved in blood vessels injury and neuroinflammation in the diabetic retina. VEGF: Vascular endothelial growth factor.

Citation: Cigrovski Berkovic M, Strollo F. Semaglutide-eye-catching results. World J Diabetes 2023; 14(4): 424-434
URL: https://www.wjgnet.com/1948-9358/full/v14/i4/424.htm
DOI: https://dx.doi.org/10.4239/wjd.v14.i4.424